Safety of 5[alpha]-reductase inhibitors and spironolactone in breast cancer patients receiving endoc...
Safety of 5[alpha]-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
About this item
Full title
Author / Creator
Publisher
Springer
Journal title
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
Purpose To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5[alpha]-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of mal...
Alternative Titles
Full title
Safety of 5[alpha]-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A578497394
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A578497394
Other Identifiers
ISSN
0167-6806
DOI
10.1007/s10549-018-4996-3
